N-cyclopropyl-3-[(6-formyl-5-methylpyrrolo[2,1-f][1,2,4]triazin-4-yl)amino]-4-methylbenzamide | 623152-56-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-cyclopropyl-3-[(6-formyl-5-methylpyrrolo[2,1-f][1,2,4]triazin-4-yl)amino]-4-methylbenzamide
• CAS: 623152-56-7
• 化学式: C₁₉H₁₉N₅O₂
• 分子量: 349.392
• InChiKey: CAFQATSBJBIOCC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  88.4
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-cyclopropyl-3-[(6-formyl-5-methylpyrrolo[2,1-f][1,2,4]triazin-4-yl)amino]-4-methylbenzamide 在 manganese(IV) oxide 、 magnesium 作用下， 以 四氢呋喃 为溶剂， 生成 N-cyclopropyl-4-methyl-3-[[5-methyl-6-(6-methylpyridine-2-carbonyl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]benzamide
  参考文献：
  名称：

  Discovery of pyrrolo[2,1-f][1,2,4]triazine C6-ketones as potent, orally active p38α MAP kinase inhibitors

  摘要：

  Pyrrolo[2,1-f][1,2,4] triazine based inhibitors of p38 alpha have been prepared exploring functional group modifications at the C6 position. Incorporation of aryl and heteroaryl ketones at this position led to potent inhibitors with efficacy in in vivo models of acute and chronic inflammation. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.05.091
• 作为产物：
  描述：

  ethyl 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methylpyrrolo[1,2-f][1,2,4]triazine-6-carboxylate 在 lithium aluminium tetrahydride 、 Jones reagent 作用下， 以 四氢呋喃 、 丙酮 为溶剂， 生成 N-cyclopropyl-3-[(6-formyl-5-methylpyrrolo[2,1-f][1,2,4]triazin-4-yl)amino]-4-methylbenzamide
  参考文献：
  名称：

  Discovery of pyrrolo[2,1-f][1,2,4]triazine C6-ketones as potent, orally active p38α MAP kinase inhibitors

  摘要：

  Pyrrolo[2,1-f][1,2,4] triazine based inhibitors of p38 alpha have been prepared exploring functional group modifications at the C6 position. Incorporation of aryl and heteroaryl ketones at this position led to potent inhibitors with efficacy in in vivo models of acute and chronic inflammation. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.05.091

文献信息

• [EN] PYRROLO-TRIAZINE ANILINE COMPOUNDS USEFUL AS KINASE INHIBITORS<br/>[FR] COMPOSES PYRROLO-TRIAZINE ANILINE UTILES EN TANT QU'INHIBITEURS DE KINASE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2003090912A1

  公开（公告）日：2003-11-06

  Compounds having the formula (I), and pharmaceutically acceptable salts, prodrugs, and solvates thereof, are useful as kinase inhibitors, wherein R1, R2, R3, R4, R5, R6, X and Z are as described in the specification.

  具有化学式（I）的化合物，以及其药学上可接受的盐、前药和溶剂化物，可用作激酶抑制剂，其中R1、R2、R3、R4、R5、R6、X和Z如规范中所述。
• PROCESS FOR PREPARING SALTS OF 4-[[5-[(CYCLOPROPYLAMINO)CARBONYL]-2-METHYLPHENYL]AMINO]-5-METHYL-N-PROPYLPYRROLO[2,1-f][1,2,4]TRIAZINE-6-CARBOXAMIDE AND NOVEL STABLE FORMS PRODUCED THEREIN
  申请人：Kim Soojin

  公开号：US20090312331A1

  公开（公告）日：2009-12-17

  Processes are provided for selectively preparing novel stable crystalline salt forms, selectively and consistently, namely, preparing Form N-1 of the methanesulfonic acid salt, and Form N-1 and Form N-4 of the hydrochloric acid salt of the p38 kinase inhibitor 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide. The processes preferably employ solvent systems including formic acid/acetone and formic acid/methylethyl ketone which produce crystals having suitable flow properties and desired particle size, and solvents such as N,N-dimethylformamide and N,N-dimethylacetamide may be employed as well. Novel Form N-1 crystals of the Form N-1 and Form N-4 crystals of the hydrochloride salt and Form N-1 crystals of the methanesulfonic acid salt of the above free base, pharmaceutical compositions containing such novel forms and a method of treating p38 kinase associated conditions, including rheumatoid arthritis are also provided.

  提供了选择性制备新型稳定晶态盐形式的过程，即有选择性和一致性地制备甲磺酸盐的N-1型和盐酸盐的N-1型和N-4型的p38激酶抑制剂4-[[5-[(环丙基氨基)羰基]-2-甲基苯基]氨基]-5-甲基-N-丙基吡咯[2,1-f][1,2,4]三嗪-6-羧酰胺。该过程最好使用包括甲酸/丙酮和甲酸/甲基乙酮的溶剂体系，产生具有适当流动性和所需粒径的晶体，也可以使用N，N-二甲基甲酰胺和N，N-二甲基乙酰胺等溶剂。还提供了上述自由基的N-1型甲磺酸盐和盐酸盐的N-1型和N-4型晶体的新型晶体形式，含有这种新型形式的药物组合物以及治疗p38激酶相关疾病，包括类风湿性关节炎的方法。
• Pyrrolo-triazine aniline compounds useful as kinase inhibitors
  申请人：Dyckman Alaric

  公开号：US20070043053A1

  公开（公告）日：2007-02-22

  Compounds having the formula (I), and pharmaceutically acceptable salts, prodrugs, and solvates thereof, are useful as kinase inhibitors, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , X and Z are as described in the specification.
• Pyrrolo-Triazine Aniline Compounds Useful As Kinase Inhibitors
  申请人：Dyckman Alaric

  公开号：US20090105243A1

  公开（公告）日：2009-04-23

  Compounds having the formula (I), and pharmaceutically acceptable salts, prodrugs, and solvates thereof, are useful as kinase inhibitors, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , X and Z are as described in the specification.
• PYRROLO-TRIAZINE ANILINE COMPOUNDS USEFUL AS KINASE INHIBITORS
  申请人：Dyckman Alaric

  公开号：US20100240646A1

  公开（公告）日：2010-09-23

  Compounds having the formula (I), and pharmaceutically acceptable salts, prodrugs, and solvates thereof, are useful as kinase inhibitors, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , X and Z are as described in the specification.